Table 2.
Placebo | L-citrulline | Adjusted | ||||||
---|---|---|---|---|---|---|---|---|
Pre | Post | Change | Pre | Post | Change | P value† | P value | |
Women | Model 1, 2 | |||||||
Seated systolic BP (mmHg) | 129 ± 15 | 130 ± 10 | 1.0 ± 8.0 | 127 ± 12 | 128 ± 15 | 0.1 ± 9.7 | 0.73 | 0.76, 0.89 |
Seated diastolic BP (mmHg) | 64 ± 7 | 66 ± 6 | 2.0 ± 5.0 | 65 ± 7 | 64 ± 7 | −1.4 ± 4.2 | 0.05 | <0.01,<0.01 |
Carotid-femoral PWV (m/s) | 8.9 ± 1.5 | 9.1 ± 1.7 | 0.2 ± 1.1 | 9.0 ± 1.5 | 9.0 ± 1.4 | 0.1 ± 0.4 | 0.77 | 0.69, 0.74 |
Plasma NOx (µmol/L) | 34 ± 11 | 36 ± 15 | 1.2 ± 10.2 | 34 ± 16 | 31 ± 10 | −3.3 ± 13.9 | 0.50 | 0.46, 0.31 |
Plasma L-arginine (µmol/L) | 96 ± 47 | 105 ± 56 | 9.2 ± 33.2 | 101 ± 36 | 144 ± 44* | 43.3 ± 38.8 | 0.02 | 0.03, 0.05 |
Men | ||||||||
Seated systolic BP (mmHg) | 135 ± 11 | 132 ± 11 | −2.7 ± 12.1 | 135 ± 14 | 132 ± 13 | −2.5 ± 5.3 | 0.87 | 0.73, 0.64 |
Seated diastolic BP (mmHg) | 74 ± 9 | 73 ± 6 | −0.5 ± 7.6 | 75 ± 9 | 71 ± 6* | −3.9 ± 5.3 | 0.04 | 0.05, 0.17 |
Carotid-femoral PWV (m/s) | 8.8 ± 1.2 | 8.8 ± 1.0 | −0.1 ± 0.4 | 8.7 ± 1.2 | 8.8 ± 1.2 | 0.1 ± 0.7 | 0.26 | 0.31, 0.67 |
Plasma NOx (µmol/L) | 32 ± 10 | 32 ± 12 | −0.1 ± 5.7 | 33 ± 8 | 33 ± 10 | 0.2 ± 11.0 | 0.87 | 0.95, 0.72 |
Plasma L-arginine (µmol/L) | 96 ± 54 | 94 ± 37 | −2.3 ± 39.1 | 78 ± 29 | 119 ± 50* | 37.4 ± 31.9 | 0.01 | <0.01, 0.03 |
Values are mean ± SD. BP, blood pressure, PWV, pulse wave velocity; NOx, nitrite and nitrate; NS, P-value greater than 0.05.
, comparison of the change value between conditions after controlling for sequence and period effects in a crossover design.
, difference (P < 0.05) between pre and post values within condition.
Model 1 adjusted for order, period, and baseline body mass index. Model 2 adjusted for model 1 plus baseline seated diastolic BP.